Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT02940301 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

Ohio State University Comprehensive Cancer Center